Skip to main content
SpringerLink
Log in

Ceftobiprole medocaril is an effective treatment against methicillin-resistant Staphylococcus aureus (MRSA) mediastinitis in a rat model

  • Article
  • Published:
European Journal of Clinical Microbiology & Infectious Diseases Aims and scope Submit manuscript

Abstract

Methicillin-resistant Staphylococcus aureus (MRSA) mediastinitis after median sternotomy is a major complication of cardiac surgery with significant morbidity and mortality rates. We evaluated the efficacy of ceftobiprole medocaril in a new rat model of mediastinitis and compared it to vancomycin. The model was induced in 92 rats. Infection was induced immediately after median sternotomy by the injection of MRSA (strain 3020, 1 × 107 cfu/rat) into the sternal bone. After 24 h, rats (groups of 6–8) were treated intraperitoneally for 5 days or 14 days by either: (i) saline (control, q8h), (ii) ceftobiprole medocaril (70 or 100 mg/kg, q8h), or (iii) vancomycin (50 mg/kg, q12h). Efficacy was determined by a reduction in bacterial cfu in the sternum and spleen tissues. Comparisons were performed using the Mann–Whitney test. A 5-day treatment course of ceftobiprole at both doses tested lead to a significant reduction in MRSA load in the sternum (p < 0.01) as compared to the control group and compared to 5-day vancomycin treatment, which lead to a non-significant reduction (p = 0.07). Longer treatment (14 days) with ceftobiprole lead to a complete clearance of MRSA from the sternum, similarly to vancomycin. Ceftobiprole also showed a significant effect on eliminating MRSA dissemination to the spleen compared to saline-treated rats. Ceftobiprole was effective in treating MRSA mediastinitis in the rat model. In the 5-day course, ceftobiprole showed a significant reduction in sternal MRSA counts and was superior to vancomycin. After 14 days, both ceftobiprole and vancomycin showed clearance of MRSA from the sternum in more than 50 % of rats and almost complete clearance in the remainder.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1

Similar content being viewed by others

References

  1. National Nosocomial Infections Surveillance System (2002) National Nosocomial Infections Surveillance (NNIS) system report, data summary from January 1992 to June 2002, issued August 2002. Am J Infect Control 30:458–475

    Article  Google Scholar 

  2. Milano CA, Kesler K, Archibald N et al (1995) Mediastinitis after coronary artery bypass graft surgery. Risk factors and long-term survival. Circulation 92:2245–2251

    Article  CAS  PubMed  Google Scholar 

  3. Kappstein I, Schulgen G, Fraedrich G et al (1992) Added hospital stay due to wound infections following cardiac surgery. Thorac Cardiovasc Surg 40:148–151

    Article  CAS  PubMed  Google Scholar 

  4. Asensio A, Torres J (1999) Quantifying excess length of postoperative stay attributable to infections: a comparison of methods. J Clin Epidemiol 52:1249–1256

    Article  CAS  PubMed  Google Scholar 

  5. Hollenbeak CS, Murphy D, Dunagan WC et al (2002) Nonrandom selection and the attributable cost of surgical-site infections. Infect Control Hosp Epidemiol 23:177–182

    Article  PubMed  Google Scholar 

  6. Jenney AW, Harrington GA, Russo PL et al (2001) Cost of surgical site infections following coronary artery bypass surgery. ANZ J Surg 71:662–664

    Article  CAS  PubMed  Google Scholar 

  7. Sharma M, Berriel-Cass D, Baran J Jr (2004) Sternal surgical-site infection following coronary artery bypass graft: prevalence, microbiology, and complications during a 42-month period. Infect Control Hosp Epidemiol 25:468–471

    Article  PubMed  Google Scholar 

  8. Fowler VG Jr, Kaye KS, Simel DL et al (2003) Staphylococcus aureus bacteremia after median sternotomy: clinical utility of blood culture results in the identification of postoperative mediastinitis. Circulation 108:73–78

    Article  PubMed  Google Scholar 

  9. Tammelin A, Hambraeus A, Ståhle E (2002) Mediastinitis after cardiac surgery: improvement of bacteriological diagnosis by use of multiple tissue samples and strain typing. J Clin Microbiol 40:2936–2941

    Article  PubMed Central  PubMed  Google Scholar 

  10. Muñoz P, Menasalvas A, Bernaldo de Quirós JC et al (1997) Postsurgical mediastinitis: a case–control study. Clin Infect Dis 25:1060–1064

    Article  PubMed  Google Scholar 

  11. Jakob HG, Borneff-Lipp M, Bach A et al (2000) The endogenous pathway is a major route for deep sternal wound infection. Eur J Cardiothorac Surg 17:154–160

    Article  CAS  PubMed  Google Scholar 

  12. Dodds Ashley ES, Carroll DN, Engemann JJ et al (2004) Risk factors for postoperative mediastinitis due to methicillin-resistant Staphylococcus aureus. Clin Infect Dis 38:1555–1560

    Article  CAS  PubMed  Google Scholar 

  13. Braxton JH, Marrin CA, McGrath PD et al; Northern New England Cardiovascular Disease Study Group (2000) Mediastinitis and long-term survival after coronary artery bypass graft surgery. Ann Thorac Surg 70:2004–2007

    Article  CAS  PubMed  Google Scholar 

  14. Micek ST (2007) Alternatives to vancomycin for the treatment of methicillin-resistant Staphylococcus aureus infections. Clin Infect Dis 45:S184–S190

    Article  CAS  PubMed  Google Scholar 

  15. Page MG (2006) Anti-MRSA beta-lactams in development. Curr Opin Pharmacol 6:480–485

    Article  CAS  PubMed  Google Scholar 

  16. Hebeisen P, Heinze-Krauss I, Angehrn P et al (2001) In vitro and in vivo properties of Ro 63-9141, a novel broad-spectrum cephalosporin with activity against methicillin-resistant staphylococci. Antimicrob Agents Chemother 45:825–836

    Article  CAS  PubMed Central  PubMed  Google Scholar 

  17. Entenza JM, Hohl P, Heinze-Krauss I et al (2002) BAL9141, a novel extended-spectrum cephalosporin active against methicillin-resistant Staphylococcus aureus in treatment of experimental endocarditis. Antimicrob Agents Chemother 46:171–177

    Article  CAS  PubMed Central  PubMed  Google Scholar 

  18. Vaudaux P, Gjinovci A, Bento M et al (2005) Intensive therapy with ceftobiprole medocaril of experimental foreign-body infection by methicillin-resistant Staphylococcus aureus. Antimicrob Agents Chemother 49:3789–3793

    Article  CAS  PubMed Central  PubMed  Google Scholar 

  19. Davies TA, Page MG, Shang W et al (2007) Binding of ceftobiprole and comparators to the penicillin-binding proteins of Escherichia coli, Pseudomonas aeruginosa, Staphylococcus aureus, and Streptococcus pneumoniae. Antimicrob Agents Chemother 51:2621–2624

    Article  CAS  PubMed Central  PubMed  Google Scholar 

  20. Yin LY, Calhoun JH, Thomas JK et al (2008) Efficacies of ceftobiprole medocaril and comparators in a rabbit model of osteomyelitis due to methicillin-resistant Staphylococcus aureus. Antimicrob Agents Chemother 52:1618–1622

    Article  CAS  PubMed Central  PubMed  Google Scholar 

  21. Tattevin P, Basuino L, Bauer D et al (2010) Ceftobiprole is superior to vancomycin, daptomycin, and linezolid for treatment of experimental endocarditis in rabbits caused by methicillin-resistant Staphylococcus aureus. Antimicrob Agents Chemother 54:610–613

    Article  CAS  PubMed Central  PubMed  Google Scholar 

  22. Barnea Y, Carmeli Y, Kuzmenko B et al (2008) Staphylococcus aureus mediastinitis and sternal osteomyelitis following median sternotomy in a rat model. J Antimicrob Chemother 62:1339–1343

    Article  CAS  PubMed  Google Scholar 

Download references

Funding

Unrestricted educational grant from Johnson and Johnson.

Conflict of interest

Nothing to declare.

Author information

Authors and Affiliations

  1. Division of Epidemiology & Laboratory for Molecular Epidemiology and Antimicrobials Research, Tel-Aviv Sourasky Medical Center, affiliated with the Sackler Faculty of Medicine, Tel-Aviv University, Tel-Aviv, Israel

    Y. Barnea, S. Navon-Venezia, B. Kuzmenko, N. Artzi & Y. Carmeli

  2. Department of Plastic and Reconstructive Surgery, Tel-Aviv Sourasky Medical Center, affiliated with the Sackler Faculty of Medicine, Tel-Aviv University, Tel-Aviv, Israel

    Y. Barnea

  3. Division of Epidemiology, Tel Aviv Sourasky Medical Center, 6 Weizmann St., Tel Aviv, 64239, Israel

    Y. Carmeli

Authors
  1. Y. Barnea
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. S. Navon-Venezia
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. B. Kuzmenko
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. N. Artzi
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Y. Carmeli
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Y. Carmeli.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Barnea, Y., Navon-Venezia, S., Kuzmenko, B. et al. Ceftobiprole medocaril is an effective treatment against methicillin-resistant Staphylococcus aureus (MRSA) mediastinitis in a rat model. Eur J Clin Microbiol Infect Dis 33, 325–329 (2014). https://doi.org/10.1007/s10096-013-1959-9

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s10096-013-1959-9

Keywords

Search

Navigation